Chemicals & Advanced Materials Global On demand · 24-48h

Global Pharmaceutical Grade Citric Acid Market Strategic Research Report

Global Pharmaceutical Grade Citric Acid Market Strategic Res…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Pharmaceutical Grade Citric Acid Market
$6212025
4.4%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Powder Citric Acid, Liquid Citric Acid

By Application: Pharmaceuticals, Healthcare, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Mireca International (India), ADM / Archer Daniels Midland Company (USA), Hawkins (USA), Jungbunzlauer Suisse (Switzerland), MP Biomedicals (USA), Hawkins (USA), Cargill Incorporated (USA), RZBC Group (China), Citribel (Belgium), Huangshi Xinghua Biochemical (China), Nantong Feiyu Food Technology(China), Jiangsu Kolod Food Ingredients(China), Shandong Lemon Biochemical(China)

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 113 pages
Market size 2025
$621
Million USD
Forecast CAGR
4.4%
2025-2032
Forecast 2032
$839.5
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global Pharmaceutical Grade Citric Acid market size is predicted to grow from US$ 621 million in 2025 to US$ 836 million in 2032; it is expected to grow at a CAGR of 4.4% from 2026 to 2032.

In 2025, global pharmaceutical grade citric acid production reached approximately 529 kilotons, the average price is 1200 usd/ton. Pharmaceutical grade citric acid, the essence is in line with the national pharmacopoeia standards, can be used as drugs or pharmaceutical excipients citric acid. It is not only a chemical substance, but also a kind of medicinal raw material with legal identity, which must meet the strict physiological safety requirements such as injection and oral administration.

Market Concentration and Key Players:

Internationally, the market concentration degree of pharmaceutical-grade citric acid is relatively high, mainly concentrated in developed countries such as Europe and America. For example, Cargill Incorporated and ADM and other large manufacturers; from the domestic point of view, pharmaceutical grade citric acid still has great development space.

Manufacturing Processes and Market Trends:

The mainstream production of pharmaceutical grade citric acid completely depends on Aspergillus niger submerged fermentation process, which takes corn or cassava sugar as substrate and is metabolized in fermenter with strict temperature control and pH control, which replaces the old chemical synthesis and surface fermentation method. After the fermentation broth is filtered by a plate frame to remove thalli, the fermentation broth enters a key calcium salt-sulfuric acid acidification extraction link, namely, crude acid is released by generating calcium citrate precipitate and then acidolysis, and most impurities can be effectively separated in this process. The subsequent refining process determines its "pharmaceutical grade" status. It must undergo activated carbon decolorization, ion exchange to remove heavy metals, multi-stage recrystallization and ultrafiltration for injection grade to remove endotoxin, and finally complete aseptic drying and packaging in a GMP clean environment.

At the market level, the global pharmaceutical-grade citric acid market is expected to expand steadily, with North America currently accounting for the highest proportion, while the Asia-Pacific region has the fastest growth due to pharmaceutical capacity transfer. The core driver of growth is the surge in demand for biopharmaceuticals and injectables, particularly for applications in hemodialysis, anticoagulant preservation, and mRNA vaccine buffer systems. Your European market (including Germany) is mature, but driven by green chemistry and REACH regulations, it is gradually shifting towards high-purity, low-endotoxin injection-grade products, while the supply chain is also coping with the cost pressures of raw material fluctuations and cGMP compliance.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Pharmaceutical Grade Citric Acid market?

What factors are driving Pharmaceutical Grade Citric Acid market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Pharmaceutical Grade Citric Acid market opportunities vary by end market size?

How does Pharmaceutical Grade Citric Acid break out by Shape, by Application?

This report presents a comprehensive overview of the global Pharmaceutical Grade Citric Acid market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Shape

  • Powder Citric Acid
  • Liquid Citric Acid

Segment by Structure

  • Citric Acid Anhydrous
  • Citric Acid Monohydrate

Segment by Standard

  • USP
  • EP
  • BP
  • ChP
  • JP

Segment by Application

  • Pharmaceuticals
  • Healthcare
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Pharmaceutical Grade Citric Acid market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Pharmaceuticals, Healthcare, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Pharmaceutical Grade Citric Acid Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 4.4%
Regional growth momentum
Market share by segment
Key metrics
Base value
$621
2025
Forecast
$839.5
2032
CAGR
4.4%
2025–2032
Regions
5
global
Key companies
Mireca International (India)ADM / Archer Daniels Midland Company (USA)Hawkins (USA)Jungbunzlauer Suisse (Switzerland)MP Biomedicals (USA)Hawkins (USA)Cargill Incorporated (USA)RZBC Group (China)
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Powder Citric AcidLiquid Citric Acid
By Application
PharmaceuticalsHealthcareOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Powder Citric Acid
  • 3.1.3 Liquid Citric Acid
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Pharmaceuticals
  • 4.1.3 Healthcare
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Mireca International (India)
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 ADM / Archer Daniels Midland Company (USA)
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Hawkins (USA)
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Jungbunzlauer Suisse (Switzerland)
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 MP Biomedicals (USA)
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Hawkins (USA)
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Cargill Incorporated (USA)
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 RZBC Group (China)
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Citribel (Belgium)
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Huangshi Xinghua Biochemical (China)
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Nantong Feiyu Food Technology(China)
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Jiangsu Kolod Food Ingredients(China)
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Shandong Lemon Biochemical(China)
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Pharmaceutical Grade Citric Acid market?
The global Pharmaceutical Grade Citric Acid market is estimated at US$ 621 million in 2025 (base year) and is projected to reach US$ 836 million by 2032.
How fast is the Pharmaceutical Grade Citric Acid market expected to grow?
The market is expected to grow at a CAGR of 4.4% from 2026 to 2032, expanding from US$ 621 million in 2025 to US$ 836 million in 2032, roughly 1.3 times its base-year value.
What does the Pharmaceutical Grade Citric Acid market cover?
In 2025, global pharmaceutical grade citric acid production reached approximately 529 kilotons, the average price is 1200 usd/ton. Pharmaceutical grade citric acid, the essence is in line with the national pharmacopoeia standards, can be used as drugs or pharmaceutical excipients citric acid. It is not only a chemical substance, but also a kind of medicinal raw material with legal identity, which must meet the strict physiological safety requirements such as injection and oral administration.
How is the Pharmaceutical Grade Citric Acid market segmented by shape?
By shape, the market is segmented into Powder Citric Acid and Liquid Citric Acid.
What are the key applications of Pharmaceutical Grade Citric Acid?
Key applications covered include Pharmaceuticals, Healthcare and Others.
Which companies are profiled in the Pharmaceutical Grade Citric Acid market report?
Key players profiled include Mireca International (India), ADM / Archer Daniels Midland Company (USA), Hawkins (USA), Jungbunzlauer Suisse (Switzerland), MP Biomedicals (USA), Hawkins (USA), Cargill Incorporated (USA) and RZBC Group (China), among 13 companies covered in total.
What geographies does the Pharmaceutical Grade Citric Acid market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Pharmaceutical Grade Citric Acid?
Your European market (including Germany) is mature, but driven by green chemistry and REACH regulations, it is gradually shifting towards high-purity, low-endotoxin injection-grade products, while the supply chain is also coping with the cost pressures of raw material fluctuations and cGMP compliance.
Who should buy the Pharmaceutical Grade Citric Acid market report?
The report is intended for manufacturers and solution providers, distributors and end users in Pharmaceuticals, Healthcare and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Pharmaceutical Grade Citric Acid market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.